333 related articles for article (PubMed ID: 25039274)
1. Efficacy and safety of combined radiotherapy with EGFR inhibitors and chemotherapy for laryngeal organ preservation in patients with locally advanced hypopharyngeal carcinomas.
Zhang X; Wang J; Wu W; Liu M; Zhao F; Du L; Huang D; Yang S; Ma L
Curr Cancer Drug Targets; 2014; 14(6):589-98. PubMed ID: 25039274
[TBL] [Abstract][Full Text] [Related]
2. [Non-surgical combined modality treatments for laryngeal organ preservation in advanced hypopharyngeal carcinoma].
Zhang X; Wang J; Wu W; Ma L; Liu M; Zhao F; Huang D
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jul; 49(7):558-63. PubMed ID: 25257270
[TBL] [Abstract][Full Text] [Related]
3. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
Suntharalingam M; Kwok Y; Goloubeva O; Parekh A; Taylor R; Wolf J; Zimrin A; Strome S; Ord R; Cullen KJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1845-50. PubMed ID: 21601372
[TBL] [Abstract][Full Text] [Related]
4. [Comparative analysis of clinical efficacies between induction chemotherapy and surgery combined with radiotherapy or concurrent chemoradiotherapy in advanced hypopharyngeal carcinoma].
Li ZD; Lu T
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Dec; 53(12):918-924. PubMed ID: 30585004
[No Abstract] [Full Text] [Related]
5. Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol.
Habl G; Jensen AD; Potthoff K; Uhl M; Hof H; Hajda J; Simon C; Debus J; Krempien R; Münter MW
BMC Cancer; 2010 Nov; 10():651. PubMed ID: 21108850
[TBL] [Abstract][Full Text] [Related]
6. Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial.
Janoray G; Pointreau Y; Alfonsi M; Sire C; Geoffrois L; de Raucourt D; Bardet E; Calais MH; Garaud P; Calais G
Eur J Cancer; 2020 Jul; 133():86-93. PubMed ID: 32454417
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation.
Liu WS; Hsin CH; Chou YH; Liu JT; Wu MF; Tseng SW; Lee JK; Tseng HC; Wang TH; Su MC; Lee H
BMC Cancer; 2010 Mar; 10():102. PubMed ID: 20298550
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of the clinical efficacy of definitive chemoradiotherapy for patients with hypopharyngeal cancer.
Takehana K; Kodaira T; Tachibana H; Kimura K; Shimizu A; Makita C; Tomita N; Nishikawa D; Suzuki H; Hirakawa H; Hanai N; Hasegawa Y
Jpn J Clin Oncol; 2016 Apr; 46(4):344-9. PubMed ID: 26826721
[TBL] [Abstract][Full Text] [Related]
9. Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers.
Lee NY; O'Meara W; Chan K; Della-Bianca C; Mechalakos JG; Zhung J; Wolden SL; Narayana A; Kraus D; Shah JP; Pfister DG
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):459-68. PubMed ID: 17493769
[TBL] [Abstract][Full Text] [Related]
10. Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study.
Fukada J; Shigematsu N; Takeda A; Ohashi T; Tomita T; Shiotani A; Kunieda E; Kawaguchi O; Fujii M; Kubo A
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):417-24. PubMed ID: 19409727
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
[TBL] [Abstract][Full Text] [Related]
12. [Effective analysis of non-surgical combined treatments for laryngeal organ preservation in locally advanced laryngeal carcinoma].
Yan F; Zhang X; Ma L; Liu M; Chen N; Wang J; Wu W; Huang D
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 May; 51(5):372-7. PubMed ID: 27220298
[TBL] [Abstract][Full Text] [Related]
13. Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers.
Miah AB; Bhide SA; Guerrero-Urbano MT; Clark C; Bidmead AM; St Rose S; Barbachano Y; A'hern R; Tanay M; Hickey J; Nicol R; Newbold KL; Harrington KJ; Nutting CM
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):539-47. PubMed ID: 21236602
[TBL] [Abstract][Full Text] [Related]
14. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
Dietz A; Wichmann G; Kuhnt T; Pfreundner L; Hagen R; Scheich M; Kölbl O; Hautmann MG; Strutz J; Schreiber F; Bockmühl U; Schilling V; Feyer P; de Wit M; Maschmeyer G; Jungehülsing M; Schroeder U; Wollenberg B; Sittel C; Münter M; Lenarz T; Klussmann JP; Guntinas-Lichius O; Rudack C; Eich HT; Foerg T; Preyer S; Westhofen M; Welkoborsky HJ; Esser D; Thurnher D; Remmert S; Sudhoff H; Görner M; Bünzel J; Budach V; Held S; Knödler M; Lordick F; Wiegand S; Vogel K; Boehm A; Flentje M; Keilholz U
Ann Oncol; 2018 Oct; 29(10):2105-2114. PubMed ID: 30412221
[TBL] [Abstract][Full Text] [Related]
16. A clinical study of multimodal treatment for orbital organ preservation in locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinus.
Chen NX; Chen L; Wang JL; Wang JY; Yan F; Ma L; Zhang XX
Jpn J Clin Oncol; 2016 Aug; 46(8):727-34. PubMed ID: 27207888
[TBL] [Abstract][Full Text] [Related]
17. Hypopharyngeal squamous cell carcinoma: Three-dimensional or Intensity-modulated radiotherapy? A single institution's experience.
Katsoulakis E; Riaz N; Hu M; Morris L; Sherman E; McBride S; Lee N
Laryngoscope; 2016 Mar; 126(3):620-6. PubMed ID: 26597398
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Clinical Trial of Concurrent Helical Tomotherapy plus Cetuximab Followed by Adjuvant Chemotherapy with Cisplatin and Docetaxel for Locally Advanced Nasopharyngeal Carcinoma.
Zhang X; Du L; Zhao F; Wang Q; Yang S; Ma L
Int J Biol Sci; 2016; 12(4):446-53. PubMed ID: 27019628
[TBL] [Abstract][Full Text] [Related]
19. Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer.
Tai SK; Yang MH; Wang LW; Tsai TL; Chu PY; Wang YF; Huang JL; Chang SY
Jpn J Clin Oncol; 2008 Aug; 38(8):521-7. PubMed ID: 18697758
[TBL] [Abstract][Full Text] [Related]
20. [Clinical analysis of multimodal treatment for orbital organ preservation in T4b squamous cell carcinoma of nasal cavity and paranasal sinuses].
Chen NX; Zhang XX; Chen L; Wang JL; Yan F; Ma L
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jul; 51(7):497-503. PubMed ID: 27480297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
